Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 1786 to 1800 of 8202 results

  1. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development [GID-TA10453] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. OrganOx metra for liver transplant [ID5116]

    In development [GID-TA11035] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...

    Technology appraisal guidance
    Topic selection

  4. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development [GID-HST10022] Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  5. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development [GID-TA10279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development [GID-TA10393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

    In development [GID-TA10919] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development [GID-TA10998] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]

    Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treati...

    Technology appraisal guidance
    Topic selection

  10. Infection prevention and control update

    In development [GID-QS10177] Expected publication date: TBC

    Quality standard
    In development

  11. SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

    In development [GID-MT526] Expected publication date: TBC

    Medical technologies guidance
    In development

  12. Managing common infections - antimicrobial prescribing guidelines

    In development [GID-NG10050] Expected publication date: TBC

    NICE guideline
    In development

  13. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development [GID-TA10431] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Perioperative care

    Awaiting development [GID-QS10094] Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Remimazolam for general anaesthesia [ID3796]

      Status ...

    Technology appraisal guidance
    Topic selection